

TO: Central Fax COMPANY: USPTO

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

**UNITED STATES PATENT AND
TRADEMARK OFFICE****Facsimile Transmission**

To: Name: Central Fax
 Company: USPTO
 Fax Number: 571-273-8300
 Voice Phone:

From: Name:
 Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Date and time of transmission: Monday, January 22, 2007 3:23:06 PM
Number of pages including this cover sheet: 08

USPTO

1/22/2007 3:24:23 PM

PAGE

2/008

Fax Server

TO: Central Fax COMPANY: USPTO
Jan 22 07 12:05p

4153335571

p.1

MandalMed, Inc.

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

To: Examiner Peter J. Reddig GAU 1642

Fax No. 571-273-9031

Date: January 22, 2007

From: Constance M. John

Pages: 7 including cover

Re: Appn. 10/726,198

Message: Enclosed please find the newly revised amendment and claims. Thank you for your kind assistance.

TO: Central Fax COMPANY: USPTO
Jan 22 07 12:05p

4153335571

p.2

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

In the United States Patent and Trademark Office

Appn. Number: 10/726,198
Filing Date: 12/02/2003
Applicants: John et al.
Appn. Title: Sustained Release N-Terminally Truncated Galectin-3 and
Antibodies to Galectin-3 Carbohydrate Ligands for Use in
Treating Disease
Examiner: Peter J. Reddig
GAU: 1642
Mailed:

NEW VERSION OF AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA
22313-1450

Date: January 22, 2007

Sir:

In response to the Office Action for the above-identified patent application, mailing date 12/07/2006, kindly amend the above-identified application as follows:

Claims, Status:

Original claims 1-10, and 18-24 are pending in this application.

Claims 11-17 were withdrawn from consideration.

Claims 1-7, 8-10, and 18-24 are subject to restriction and/or election requirement.

Election and Amendment of Claims:

Election of Group I (Claims 1-7) and Seq. ID No: 1. Withdrawal of Claims 8-10, and 18-24. Claims 1-7 are submitted as follows.

Claim Election/Restrictions:

Claims 1-7 (Group I) are submitted for consideration. Claims 4 and 6 are currently amended. Claim 4 was amended to included use in treatment of specific diseases in